Mostrar el registro sencillo del ítem
Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer's Disease
| dc.contributor.author | García Morales, Victoria | |
| dc.contributor.author | González Acedo, Anabel | |
| dc.contributor.author | Melguizo-Rodríguez, Lucía | |
| dc.contributor.author | Pardo-Moreno, Teresa | |
| dc.contributor.author | Costela-Ruiz, Víctor Javier | |
| dc.contributor.author | Montiel-Troya, María | |
| dc.contributor.author | Ramos-Rodríguez, Juan José | |
| dc.contributor.other | Biomedicina, Biotecnología y Salud Pública | es_ES |
| dc.date.accessioned | 2022-03-15T11:01:22Z | |
| dc.date.available | 2022-03-15T11:01:22Z | |
| dc.date.issued | 2021-12 | |
| dc.identifier.issn | 2227-9059 | |
| dc.identifier.uri | http://hdl.handle.net/10498/26432 | |
| dc.description.abstract | Alzheimer's disease (AD) is the most common cause of dementia. It is characterized by cognitive decline and progressive memory loss. The aim of this review was to update the state of knowledge on the pathophysiological mechanisms, diagnostic methods and therapeutic approach to AD. Currently, the amyloid cascade hypothesis remains the leading theory in the pathophysiology of AD. This hypothesis states that amyloid-beta (A beta) deposition triggers a chemical cascade of events leading to the development of AD dementia. The antemortem diagnosis of AD is still based on clinical parameters. Diagnostic procedures in AD include fluid-based biomarkers such as those present in cerebrospinal fluid and plasma or diagnostic imaging methods. Currently, the therapeutic armory available focuses on symptom control and is based on four pillars: pharmacological treatment where acetylcholinesterase inhibitors stand out; pharmacological treatment under investigation which includes drugs focused on the control of A beta pathology and tau hyperphosphorylation; treatment focusing on risk factors such as diabetes; or nonpharmacological treatments aimed at preventing development of the disease or treating symptoms through occupational therapy or psychological help. AD remains a largely unknown disease. Further research is needed to identify new biomarkers and therapies that can prevent progression of the pathology. | es_ES |
| dc.description.sponsorship | L.M.-R. and J.J.R.-R. are funded by P20-01293 from Junta de Andalucia, Spain. J.J.R.-R. is additionally funded by PECART-0096-2020 from Junta de Andalucia, Spain and PID2020-117544RB-100 from the Ministry of Science and Innovation, Spain. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | MDPI | es_ES |
| dc.rights | Atribución 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.source | Biomedicines 2021, 9(12), 1910 | es_ES |
| dc.subject | Alzheimer’s disease | es_ES |
| dc.subject | senile plaques | es_ES |
| dc.subject | -amyloid protein | es_ES |
| dc.subject | diagnosis | es_ES |
| dc.subject | biomarker | es_ES |
| dc.subject | treatment | es_ES |
| dc.subject | acetylcholinesterase inhibitors | es_ES |
| dc.subject | immunotherapy | es_ES |
| dc.title | Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer's Disease | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.3390/biomedicines9121910 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117544RB-I00/ES/NANOBOMBA TERMOFORETICA DIRIGIDA Y CELULAS CAR MONITORIZADAS POR NANOPARTICULAS COMO TERAPIA INMUNOLOGICA COMBINADA/ | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos Científicos [11977]
-
Articulos Científicos Biomedicina [582]
